Switching From DPP-4 Inhibitors to Oral Semaglutide Improves Blood Sugar and Weight in Japanese Diabetic Patients | Research

The takeaway

Switching from DPP-4 inhibitors to oral semaglutide reduced HbA1c from 7.8% to 7.0% and decreased body weight in 68 Japanese type 2 diabetes patients, with 95.6% improving in at least one measure.

7.8% → 7.0% HbA1c
Mean HbA1c dropped 0.8 percentage points after switching from DPP-4 inhibitor to oral semaglutide in 68 Japanese patients

What the researchers found

Switching from DPP-4i to oral semaglutide reduced mean HbA1c from 7.8% to 7.0% (P significant) and decreased body weight (P significant). 95.6% improved in either HbA1c or weight. Greater HbA1c reduction correlated with greater weight loss (r=0.480, P<0.001). 20% discontinued within 6 months.

Why it matters

DPP-4 inhibitors are the backbone of Japanese diabetes treatment but often provide insufficient control. This study shows oral semaglutide can be a practical step-up that improves both blood sugar and weight without requiring injections.

The numbers in context

68 Japanese patients were studied after switching from DPP-4 inhibitors to oral semaglutide, with improvements in both HbA1c and body weight.

How the study worked

Single-center retrospective study of 68 Japanese T2D patients switched from DPP-4 inhibitors to oral semaglutide for ≥6 months without changes to other oral hypoglycemics. Outcomes: HbA1c and body weight changes.

Who was studied

68 Japanese patients with type 2 diabetes switching from DPP-4 inhibitors to oral semaglutide

What this study cannot tell us

Retrospective, single-center, no control group. Cannot separate drug switch effect from regression to mean. 20% dropout introduces survival bias. No long-term follow-up beyond 6 months. Non-obese older patients had highest discontinuation, suggesting limited utility in this subgroup.

How to read the evidence

Moderate evidence — real-world retrospective study with meaningful sample size but no control group and notable dropout rate.

When this study was published

Published in 2024, reflecting current DPP-4i to oral semaglutide switching patterns in Japanese clinical practice.

The bigger picture

The shift from DPP-4 inhibitors to GLP-1 agonists is accelerating globally. Oral semaglutide bridges the gap by offering GLP-1-class benefits without injections, which is particularly relevant in Japan where DPP-4 inhibitors dominate and injection resistance is common.

Questions still open

Could slower dose titration reduce the 20% dropout rate seen with oral semaglutide?
Is the benefit of switching primarily from semaglutide's greater GLP-1 receptor agonism, or from a different pharmacological mechanism?
Would patients who discontinued oral semaglutide tolerate injectable semaglutide better?

Common questions

Why switch from a DPP-4 inhibitor to oral semaglutide?

DPP-4 inhibitors are effective but often don't provide enough blood sugar control or weight loss on their own. Oral semaglutide is a more potent option in the same GLP-1 pathway that can improve both measures without requiring injections.

Who might not tolerate the switch to oral semaglutide?

The study found that older, non-obese patients had the highest discontinuation rate, mainly due to gastrointestinal side effects. These patients may benefit from slower dose titration or may need to try injectable semaglutide instead.

Read the original research

Efficacy and safety of switching from a dipeptidyl peptidase-4 inhibitor to oral semaglutide in Japanese patients with type 2 diabetes mellitus.

Diabetology international, 15(3), 569-576

View on PubMed ↗Publisher’s paper ↗

Citation

Yoneda, Chihiro; Kobayashi, Junji; Kuribayashi, Nobuichi. (2024). Efficacy and safety of switching from a dipeptidyl peptidase-4 inhibitor to oral semaglutide in Japanese patients with type 2 diabetes mellitus.. Diabetology international, 15(3), 569-576. https://doi.org/10.1007/s13340-024-00734-5